Aller au contenu principal
Accès ouvert déclaré 2025 article

Exploring varicella zoster virus proteome for construction and validation of a multi-epitope based subunit vaccine using multifaceted immunoinformatics approaches

2Citations signalées, ce qui n’est pas une note de qualité
7Institutions déclarées
3Pays d’affiliation déclarés

Rattachement africain : sa, Soudan, my. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Varicella zoster (VZ) is a viral disease caused by varicella zoster virus (VZV) that is related to alphaherpesvirus subfamily. VZV causes a neurotropic disease in humans. The aim of this work was to stimulate the human immune system by developing a multi-epitope vaccine based on five VZV surface proteins. Multiple immunoinformatics techniques were applied to assess B-cell and T-cell epitopes. The population coverage of each T-cell epitope was analyzed and the results showed high population coverage scores. The vaccine consists of 615 amino acids and it was antigenic and non-allergenic. The vaccine's hydrophilicity, stability, presence of aliphatic side chains, and thermal stability were all determined through an analysis of its physical and chemical characteristics. Also the vaccine demonstrated the least homology to human proteome (11%). Using the PSIPRED server and the Ramachandran plot, the vaccine's secondary and tertiary structures were predicted, enhanced, and validated. The structural errors were assessed using the ProSA web tool. Furthermore, the vaccine's solubility was higher than that of the E. coli proteins. Following immune simulation, there were significant amounts of T-cells, INF-γ, IL-2, and antibodies. Significant docking scores were obtained for each predicted epitopes and for the vaccine when docked to TLR4 chains. The TLR4-vaccine complex was highly stable according to molecular dynamic modeling. In silico cloning was performed to assess the vaccine's expression in the pET28a(+) vector, and the cloning results were efficient for translation. To ascertain the vaccine's effectiveness, in vivo and in vitro investigations, including clinical trials are required.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Exploring varicella zoster virus proteome for construction and validation of a multi-epitope based subunit vaccine using multifaceted immunoinformatics approaches
Date Crossref
24/06/2025
Éditeur
Public Library of Science (PLoS)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

vaccines and immunoinformatics approachesMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune Responses

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.